Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: Data from the JAVELIN Solid Tumor trial.

被引：9

作者：

Gulley, James L.

Spigel, David R.

Kelly, Karen

Aisner, Joseph

Chand, Vikram K.

Koenig, Andre

Dolgos, Hugues

Wang, Shaonan

Verschraegen, Claire F.

机构：

[1] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Univ Calif Davis, Comprehensive Canc Ctr, Sacramento, CA 95817 USA

[4] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[5] EMD Serono Inc, Billerca, MA USA

[6] Merck KGaA, Darmstadt, Germany

[7] Univ Vermont, Canc Ctr, Burlington, VT USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.9086

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9086

引用

页数：6